Dyne Therapeutics (NASDAQ:DYN - Get Free Report)'s stock had its "sell (d-)" rating reissued by research analysts at Weiss Ratings in a report issued on Friday,Weiss Ratings reports.
Other analysts also recently issued research reports about the company. Royal Bank Of Canada decreased their target price on Dyne Therapeutics from $25.00 to $23.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 29th. Chardan Capital dropped their target price on shares of Dyne Therapeutics from $50.00 to $38.00 and set a "buy" rating for the company in a research report on Tuesday, July 29th. Jones Trading began coverage on shares of Dyne Therapeutics in a research note on Thursday, June 26th. They issued a "buy" rating and a $30.00 price target on the stock. Evercore ISI reiterated an "outperform" rating on shares of Dyne Therapeutics in a research note on Friday, July 11th. Finally, Lifesci Capital raised Dyne Therapeutics to a "strong-buy" rating in a report on Tuesday, October 14th. Four equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $34.07.
Get Our Latest Stock Analysis on Dyne Therapeutics
Dyne Therapeutics Stock Performance
DYN opened at $17.12 on Friday. The company has a current ratio of 16.83, a quick ratio of 16.83 and a debt-to-equity ratio of 0.17. The company has a market cap of $2.44 billion, a price-to-earnings ratio of -4.44 and a beta of 1.09. The company's 50 day moving average is $13.80 and its 200 day moving average is $11.72. Dyne Therapeutics has a 12-month low of $6.36 and a 12-month high of $35.68.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Monday, July 28th. The company reported ($0.97) earnings per share for the quarter, beating analysts' consensus estimates of ($0.99) by $0.02. On average, equities research analysts predict that Dyne Therapeutics will post -3.44 EPS for the current year.
Insider Activity at Dyne Therapeutics
In related news, CEO John Cox sold 2,640 shares of Dyne Therapeutics stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $13.41, for a total transaction of $35,402.40. Following the completion of the transaction, the chief executive officer directly owned 199,539 shares of the company's stock, valued at approximately $2,675,817.99. The trade was a 1.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 14.14% of the company's stock.
Institutional Trading of Dyne Therapeutics
Several institutional investors have recently added to or reduced their stakes in the company. CWM LLC raised its holdings in shares of Dyne Therapeutics by 168.1% in the second quarter. CWM LLC now owns 3,030 shares of the company's stock worth $29,000 after buying an additional 1,900 shares during the period. Caitong International Asset Management Co. Ltd grew its position in Dyne Therapeutics by 378.6% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company's stock valued at $32,000 after acquiring an additional 2,446 shares during the last quarter. Quarry LP bought a new position in Dyne Therapeutics in the 1st quarter valued at $47,000. Ameritas Investment Partners Inc. grew its position in Dyne Therapeutics by 11.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company's stock valued at $91,000 after acquiring an additional 955 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its position in Dyne Therapeutics by 275.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company's stock valued at $100,000 after acquiring an additional 7,697 shares during the last quarter. Institutional investors own 96.68% of the company's stock.
About Dyne Therapeutics
(
Get Free Report)
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dyne Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.
While Dyne Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
